ライフサイエンスコーパス: fetoprotein

1 for alkaline phosphatase, P<.0001 for alpha-fetoprotein).

2 clinical diagnosis and was superior to alpha-fetoprotein.

3 epatic neoplasia and increase in serum alpha-fetoprotein.

4 tive of tumor burden or serum level of alpha-fetoprotein.

5 umors that express increased levels of alpha-fetoprotein.

6 MELD score, HCC size, HCC number, and alpha-fetoprotein.

7 vasion, metastasis, serum albumin, and alpha-fetoprotein.

8 ression of fetal liver genes including alpha-fetoprotein.

9 omitantly with increased expression of alpha-fetoprotein.

10 m increase [1.04-1.11]; p<0.0001), log alpha-fetoprotein (1.10 per unit increase [1.02-1.20]; p=0.018

11 patients with an elevated pretreatment alpha-fetoprotein, 85% were found to have declining alpha-feto

12 homogeneous liquid-phase detection of alpha-fetoprotein, a common tumor marker, the system shows a g

13 tion of beta-catenin and expression of alpha-fetoprotein, a prognostic marker of hepatocellular carci

14 -fetoprotein (MSAFP) or amniotic fluid alpha-fetoprotein (AFAFP) levels or abnormalities visualized o

15 High alpha-fetoprotein (AFP) > 1,000 ng/mL is associated with poor

16 Elevated alpha-fetoprotein (AFP) >/= 10,000 ng/mL was associated with w

17 d ratio [HR], 3.1; P = 0.005) and with alpha-fetoprotein (AFP) >= 100 ng/mL at LT (HR, 2.4; P = 0.009

18 Most strikingly, patients with an alpha-fetoprotein (AFP) >=10 ng/mL and having used sirolimus f

19 In multivariate analysis, only alpha-fetoprotein (AFP) >=200 ng/mL (P = 0.006) and large tumo

20 ysis for patients with a high level of alpha-fetoprotein (AFP) (>100 ng/dL) was conducted.

21 apy levels of serum tumor markers were alpha-fetoprotein (AFP) 2.0 ng/mL, human chorionic gonadotropi

22 Mean preoperative serum alpha-fetoprotein (AFP) and beta-human chorionic gonadotropin

23 We used two model biomarkers [alpha-fetoprotein (AFP) and cancer antigen 125 (CA125)] to dem

24 s study was to compare the accuracy of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP

25 vels of alkaline phosphatase (ALP) and alpha-fetoprotein (AFP) and lower level of alanine aminotransf

26 HCC surveillance with alpha-fetoprotein (AFP) and ultrasonography has been recommend

27 ommendation through the examination of alpha-fetoprotein (AFP) and ultrasound for patients at risk in

28 We identified alpha-fetoprotein (AFP) and ultrasound tests performed for HCC

29 Serum levels of alpha-fetoprotein (AFP) are influenced not only by the presenc

30 In addition, we have identified the alpha-fetoprotein (AFP) as a novel downstream target of NF-kap

31 Median alpha fetoprotein (AFP) at diagnosis and pre-LDLT were 78.1 ng

32 Twenty-three patients had elevated alpha-fetoprotein (AFP) at diagnosis.

33 accounting for etiology of cirrhosis, alpha-fetoprotein (AFP) at liver transplant, tumor diameter, t

34 ansplant (RETREAT), which incorporates alpha-fetoprotein (AFP) at liver transplantation (LT), microva

35 ate quantitation of biomarkers such as alpha-fetoprotein (AFP) can be a key aspect of early stage can

36 ears, 3-7 years, and 8 years or older; alpha fetoprotein (AFP) concentration of 100 ng/mL or lower an

37 e HCC-associated self/tumor antigen of alpha-fetoprotein (AFP) could be engineered to create an effec

38 We previously showed that mouse alpha-fetoprotein (AFP) enhancer 3 activity is highly restrict

39 on under the control of an albumin and alpha-fetoprotein (AFP) enhancer and promoter (AFP-Notch intra

40 Although alpha-fetoprotein (Afp) falls into this class of genes, as it

41 Aberrant expression of the alpha-fetoprotein (AFP) gene is a diagnostic tumor marker of h

42 The alpha-fetoprotein (AFP) gene is expressed abundantly in the fe

43 e promoter of the hepatic tumor marker alpha-fetoprotein (AFP) gene.

44 tumor diameter of 3 to 5 cm and serum alpha fetoprotein (AFP) greater than 100 ng/mL at transplant y

45 neutrophil-lymphocyte ratio (NLR) and alpha-fetoprotein (AFP) have been associated with recurrence r

46 (AST)-platelet ratio index (APRI) and alpha fetoprotein (AFP) in Ghana.

47 ce status, Child-Pugh score (CPS), and alpha-fetoprotein (AFP) in predicting individual survival.

48 to be more sensitive and specific than Alpha-fetoprotein (AFP) in the diagnosis of HCC among the Whit

49 alpha-Fetoprotein (AFP) independently predicted tumor recurren

50 Alpha-fetoprotein (AFP) is a biomarker for hepatocellular carc

51 Serum alpha-fetoprotein (AFP) is a biomarker for hepatocellular carc

52 The L3 isoform of alpha-fetoprotein (AFP) is a specific marker for hepatocellula

53 alpha-Fetoprotein (AFP) is an oncofetal Ag and has intrinsic i

54 alpha-fetoprotein (AFP) is an oncofetal Ag that is highly expr

55 Alpha-fetoprotein (AFP) is considered to be an indicator of tu

56 ensitive detection of cancer biomarker alpha-fetoprotein (AFP) is described that uses a graphene shee

57 d expression of the hepatoblast marker alpha-fetoprotein (Afp) is lost.

58 Alpha-fetoprotein (AFP) is often expressed at high levels in H

59 Although serum alpha-fetoprotein (AFP) is often used to detect hepatocellular

60 HCC), because the sensitivity of serum alpha-fetoprotein (AFP) is too low for this purpose.

61 Alpha-fetoprotein (AFP) is widely used as a surveillance test

62 ified substantial necrosis, high serum alpha-fetoprotein (AFP) level (>100 ng/mL), and Barcelona Clin

63 hort of 721 patients (542 men), median alpha-fetoprotein (AFP) level at the time of LT was 8.3 ng/mL;

64 staging system, tumor size, and serum alpha-fetoprotein (AFP) level were investigated using Cox prop

65 mph node metastases and a rising serum alpha-fetoprotein (AFP) level.

66 Nonetheless, serial measurement of alpha-fetoprotein (AFP) levels in serum and hepatic ultrasound

67 in terms of toxicity, tumor response, alpha-fetoprotein (AFP) levels, and serum arginine levels.

68 with tumor histology and pretransplant alpha-fetoprotein (AFP) levels.

69 testing disclosed a slightly elevated alpha-fetoprotein (AFP) of 12.3 ug/L (upper limit of normal, 8

70 dentify a biomarker that could improve alpha-fetoprotein (AFP) performance in hepatocellular carcinom

71 Alpha-fetoprotein (AFP) represents a classical model system to

72 group has shown that a rising natural alpha-fetoprotein (AFP) slope (NAS) correlates with tumor char

73 Although surveillance ultrasound and alpha fetoprotein (AFP) tests have minimal direct harm, downst

74 r p53 in the regulation of the hepatic alpha-fetoprotein (AFP) tumor marker gene.

75 nt assay was developed to detect human alpha-fetoprotein (AFP) using carbon dots (C-Dots).

76 In 17 patients the baseline serum alpha-fetoprotein (AFP) was >or= 1,000 ng/mL; in four of these

77 The AUC value for alpha-fetoprotein (AFP) was 0.80 (0.74-0.87) compared to 0.94

78 e the device under optimal conditions, alpha-fetoprotein (AFP) was detected at a limit of detection o

79 nique serum levels of IL-6, IL-10, and alpha fetoprotein (AFP) were evaluated in all groups.

80 Levels of human alpha-fetoprotein (AFP) were monitored in the serum of animals

81 epatitis B surface antigen (HBsAg) and alpha-fetoprotein (AFP) with the lowest concentration of naked

82 ion molecule (EpCAM)(+) HCC cells from alpha-fetoprotein (AFP)(+) tumors with cancer stem/progenitor

83 s12979860), serum 25OH-vitamin D, serum alfa-fetoprotein (AFP)) were performed on a cohort of 200 Egy

84 h activated Wnt signaling occupying an alpha-fetoprotein (AFP)+/cytokeratin-19 (CK-19)-positive proge

85 As demonstrated on alpha-fetoprotein (AFP), a serum biomarker for hepatocellular

86 hepatic associated gene expression of alpha-fetoprotein (AFP), Albumin (Alb), Glucose-6-phosphatase

87 inoembryonic antigen (CEA), bilirubin, alpha fetoprotein (AFP), and c-reactive protein (CRP) were ide

88 some potential advantages compared to alpha-fetoprotein (AFP), but its role in the context of alcoho

89 rkers: carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), cancer antigen 125 (CA125), and carbo

90 arbohydrate antigen 19-9 (CA 19-9) and alpha-fetoprotein (AFP), commonly used to help in the diagnosi

91 The fetal hepatocytes expressed alpha-fetoprotein (AFP), cytokeratin (CK) 19, albumin, and oth

92 erlapping peptides spanning the entire alpha-fetoprotein (AFP), glypican-3 (GPC-3), melanoma-associat

93 The conventional serum marker for HB, alpha-fetoprotein (AFP), has its limitations.

94 or markers of visceral endoderm (DAB2, alpha-fetoprotein (AFP), HNF4).

95 ctor required for HSC homing, and also alpha-fetoprotein (AFP), indicating that they are fetal hepati

96 atocellular carcinoma (HCC) biomarkers alpha-fetoprotein (Afp), insulin-like growth factor 2 (Igf2),

97 They are negative for alpha-fetoprotein (AFP), intercellular adhesion molecule (ICAM

98 y associated with elevated circulating alpha-fetoprotein (AFP), low rate of necrosis/fibrosis after t

99 Serum alpha-fetoprotein (AFP), normally highly expressed in the live

100 dominant and subdominant epitopes from alpha fetoprotein (AFP), restricted by HLA-A*0201, which are r

101 A expression was associated with serum alpha-fetoprotein (AFP), tumor-node-metastasis (TNM) stage, an

102 this approach, an aptamer specific to alpha-fetoprotein (AFP), which is a biomarker for liver cancer

103 lymer (MIP) for trace level sensing of alpha-fetoprotein (AFP), which is a well know cancer biomarker

104 (MELD-Na), tumour burden score (TBS), alpha-fetoprotein (AFP), year of transplantation, underlying c

105 nsitive detection of cancer biomarker, alpha-fetoprotein (AFP).

106 direct and ultrasensitive detection of alpha-fetoprotein (AFP).

107 pmental repression of the tumor marker alpha-fetoprotein (AFP).

108 mplication by determining the level of alpha-fetoprotein (AFP).

109 19, albumin +/-, and are negative for alpha-fetoprotein (AFP).

110 HCC in Japanese patients compared with alpha-fetoprotein (AFP).

111 of the transcription factor SOX-17 and alpha-fetoprotein (AFP).

112 n biomarker panel [APOH, ORM2, C3, and alpha-fetoprotein (AFP)] has proven to outperform AFP, the kno

113 otal tumor volume (TTV; </=115 cm(3) )/alpha-fetoprotein (AFP; </=400 ng/mL) score.

114 ence as well as patients with negative alpha-fetoprotein (AFP; n = 1), resulting in 24 patients and 5

115 ntly identified HCC subtypes (EpCAM(+) alpha-fetoprotein [AFP(+)] HCC and EpCAM(-) AFP(-) HCC).

116 associated self-antigens (for example, alpha-fetoprotein [AFP]).

117 ibodies specific for epithelial cells (alpha-fetoprotein [AFP], albumin [ALB], pancytokeratin [PanCK]

118 l recommended measuring three markers (alpha-fetoprotein [AFP], human chorionic gonadotropin [hCG], a

119 The vast majority of alpha fetoprotein(+), albumin(+), cytokine-19(+), and E-cadher

120 lpha-fetoprotein and ferritin or serum alpha-fetoprotein alone, including four with coagulopathy (int

121 n gene family is comprised of albumin, alpha-fetoprotein, alpha-albumin (afamin), and the more distan

122 the serum transport proteins albumin, alpha-fetoprotein, alpha-albumin, and vitamin D-binding protei

123 nogen, fibronectin, transthyretin, and alpha-fetoprotein, an essential feature for functional HE.

124 t this enhancer region is required for alpha-fetoprotein and albumin activation early in liver develo

125 re analyzed by immunocitochemistry for alpha-fetoprotein and albumin expression, qPCR for hepatocyte

126 that RNA polymerase II loading on the alpha-fetoprotein and albumin promoters is reduced in the abse

127 ed (45-70%) for cells that express the alpha-fetoprotein and albumin proteins.

128 er of a cluster that includes albumin, alpha-fetoprotein and alpha-albumin genes.

129 e genes, particularly that of albumin, alpha-fetoprotein and alpha-albumin, and their liver-specific

130 Serum and CSF alpha-fetoprotein and beta-human chorionic gonadotropin levels

131 nd cerebrospinal fluid (CSF) levels of alpha-fetoprotein and beta-subunit of human chorionic gonadotr

132 Plasma levels of alpha-fetoprotein and c-MET were associated with poor outcome

133 er than normal concentrations of serum alpha-fetoprotein and ferritin or serum alpha-fetoprotein alon

134 The prognostic information provided by alpha-fetoprotein and human chorionic gonadotrophin in the man

135 Serum tumor markers alpha-fetoprotein and human chorionic gonadotrophin were corre

136 142 mEq/L [134-142 mmol/L]), and serum alpha-fetoprotein and human chorionic gonadotropin levels were

137 Molecular markers of HCC, alpha-fetoprotein and p53, were increased in tumors of Txnip-d

138 tic regression selected combined serum alpha-fetoprotein and portal flow (F (p) ) skewness (area unde

139 with induction of the human HCC marker alpha-fetoprotein and the stem cell marker CD133.

140 ond-trimester levels of maternal serum alpha-fetoprotein and the subsequent risk of SIDS.

141 l transferase activity, elevated serum alpha-fetoprotein and undetectable liver bile salt export pump

142 with slow serum tumor marker decline (alpha-fetoprotein and/or human chorionic gonadotrophin) during

143 ession/coexpression of DCAMKL-1, CK19, alpha-fetoprotein, and active c-Src.

144 liver phenotype: albumin, transferrin, alpha-fetoprotein, and alpha1-antitrypsin.

145 he expression of biliary cytokeratins, alpha-fetoprotein, and c-Met by FIHC.

146 ge liver disease scores, pretransplant alpha fetoprotein, and cumulative tumor diameters; were more l

147 eted hepatic proteins such as Albumin, Alpha Fetoprotein, and Fibrinogen, metabolized ammonia, and di

148 of beta-human chorionic gonadotropin, alpha-fetoprotein, and lactate dehydrogenase.

149 Age, LRT status, serum alpha1-fetoprotein, and microvascular invasion were independent

150 xpressed both donor marker (DPPIV) and alpha-fetoprotein, and some differentiated into hepatocytes.

151 vel expression of active beta-catenin, alpha-fetoprotein, and SOX9, suggesting that DCLK1 overexpress

152 bilirubin, albumin, prothrombin time, alpha-fetoprotein, and tumor number, which were incorporated i

153 ion; levels of bilirubin, albumin, and alpha-fetoprotein; and WHO/EASL response rate predicted surviv

154 K18, glutathione S-transferase alpha, alpha-fetoprotein, arginase-1, osteopontin (OPN), sorbitol deh

155 stage, tumour histology, and levels of alpha-fetoprotein at diagnosis to receive risk-adapted therapy

156 alpha-Fetoprotein, beta-human chorionic gonadotropin, and lact

157 with HBV had larger tumors and higher alpha-fetoprotein but less satellites and macrovascular invasi

158 g cytoplasmic/nuclear beta-catenin and alpha-fetoprotein but not CK19, HNF1beta, or Trop-2.

159 , primary site, treatment, and elevated alfa fetoprotein by univariate and multivariate analysis.

160 met+, SSEA-4+, CK18+, CK19+, albumin-, alpha-fetoprotein-, CD44h+, and vimentin+.

161 ignificantly different among the three alpha-fetoprotein classes (P = 0.493).

162 ording to randomising centre and serum alpha-fetoprotein concentration (<400 ng/mL and >/=400 ng/mL).

163 ahepatic spread, or both; and baseline alpha-fetoprotein concentration.

164 hepatocellular carcinoma and increased alpha-fetoprotein concentrations have poor prognosis.

165 (ECOG) performance statuses of 0 or 1, alpha-fetoprotein concentrations of 400 ng/mL or greater, and

166 REACH (NCT01140347) for patients with alpha-fetoprotein concentrations of 400 ng/mL or greater.

167 advanced hepatocellular carcinoma and alpha-fetoprotein concentrations of 400 ng/mL or higher.

168 ents with hepatocellular carcinoma and alpha-fetoprotein concentrations of at least 400 ng/mL who had

169 d serum human chorionic gonadotropin or alfa-fetoprotein concentrations that matched International Ge

170 ients' human chorionic gonadotropin and alfa-fetoprotein concentrations were measured at day 18-21.

171 ine in human chorionic gonadotropin and alfa-fetoprotein continued BEP (Fav-BEP group) for 3 additona

172 was assessed by expression of albumin, alpha-fetoprotein, cytochrome P4502E1, cytokeratin-18, type-1

173 Rat ED14 FLSPC are alpha-fetoprotein(+)/cytokeratin-19(+) or alpha-fetoprotein(+)

174 ha-fetoprotein(+)/cytokeratin-19(+) or alpha-fetoprotein(+)/cytokeratin-19(-) and contain all of the

175 and embryonal carcinomas positive for alpha-fetoprotein, cytokeratin AE1/AE3, and CD30.

176 kinase-like-1 (DCAMKL-1), Lgr5, CD133, alpha-fetoprotein, cytokeratin-19 (CK19), Lin28, and c-Myc.

177 zones were simultaneously positive for alpha-fetoprotein, cytokeratin-19, and c-kit, indicating their

178 press the classical oval cell markers (alpha-fetoprotein, cytokeratin-19, OV-1 antigen, a6 integrin,

179 when the values of known serum markers alpha fetoprotein, des-gamma carboxyprothrombin, and GP73 were

180 ia (n = 1), and 1 patient treated with alpha-fetoprotein-directed CAR T cells for hepatocellular carc

181 A raised maternal serum level of alpha-fetoprotein during the second trimester of pregnancy is

182 aced the endodermal enhancers with the alpha-fetoprotein endodermal enhancers (H19Afp).

183 g Cre-recombinase under control of the alpha fetoprotein enhancer and albumin promoter.

184 To directly examine whether the alpha-fetoprotein enhancer region could regulate the albumin g

185 he control of the albumin promoter and alpha-fetoprotein enhancer to ablate Jag1 in hepatoblasts.

186 ression of vimentin, beta-III tubulin, alpha-fetoprotein, eomesodermin, HEB, ARNT, and FoxD3 as well

187 bdominal computed tomography and serum alpha-fetoprotein every 6 months.

188 ormed using ultrasound with or without alpha-fetoprotein every 6 months.

189 ell proliferation and a lower level of alpha-fetoprotein expression as compared with control animals.

190 duced albumin expression and decreased alpha-fetoprotein expression in HepG2 cells, which suggests th

191 s of the similarities between Gpc3 and alpha-fetoprotein expression in the liver, we reasoned that co

192 pression caused a dramatic decrease in alpha-fetoprotein expression, implying impaired oval cell acti

193 ning (absent or diffuse), and variable alpha-fetoprotein expression.

194 spalt-like transcription factor 4, and alpha-fetoprotein expression; and high coordinated expression

195 atocyte nuclear factor 4 (HNF-4), HNF-3, and fetoprotein factor to the precore/core promoter enhancer

196 The albumin and alpha-fetoprotein genes are adjacent and express closely relat

197 n patients older than 60 years, serum alpha1-fetoprotein greater than 400 mg/L, bilobar distribution,

198 , 0.3; 95% CI, 0.2-0.7; P = 0.003) and alpha-fetoprotein > 100 ng/mL (HR, 2.5; 95% CI, 1.1-5.0, P = 0

199 8.5 years); 109 were female; and 99 had alfa fetoprotein > or = 10,000.

200 ownstaging group included pretreatment alpha-fetoprotein >/=1,000 ng/mL (multivariate hazard ratio [H

201 ing treatment failure was pretreatment alpha-fetoprotein >1,000 ng/mL.

202 ase (HR, 1.66; 95% CI, 1.02-2.71), and alpha-fetoprotein >1000 ng/mL (HR, 1.86; 95% CI, 1.22-2.84) we

203 identified age <65 years (P = 0.038), alpha-fetoprotein >200 ng/mL (P = 0.04), and vascular invasion

204 nib, or ramucirumab (for patients with alpha-fetoprotein >= 400 ng/mL), or atezo + bev where patients

205 nvasion, exceeding Milan criteria, and alpha-fetoprotein>200 ng/mL.

206 tumors, presence of metastases, serum alpha-Fetoprotein, hepatitis serologies, severity of hepatic d

207 They also expressed alpha-fetoprotein, hepatocyte nuclear factor-4a, and a metabol

208 inical diagnostic application, such as alpha-fetoprotein in liver carcinoma, and kallikreins 6 and 10

209 ate the prognostic usefulness of serum alpha-fetoprotein in patients with well-compensated cirrhosis,

210 ty of des-gamma-carboxyprothrombin and alpha-fetoprotein in the diagnosis of hepatocellular carcinoma

211 a clinically relevant assay to detect alpha-fetoprotein, in which a 42-fold enhancement to sensitivi

212 he proposed Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) score was the best pred

213 /alanine aminotransferase (ALT) ratio, alpha-fetoprotein, insulin, and homeostatic model assessment (

214 Alpha-fetoprotein is a tumor marker that has been used for sur

215 Alpha-fetoprotein is the most widely used tumor marker, but ha

216 atio, 1.61; 95% CI: 1.3-2.1) and serum alpha-fetoprotein level >/=455 ng/mL (hazard ratio, 2.15; 95%

217 nts with larger (3-5 cm) tumors, serum alpha-fetoprotein level >/=455 ng/mL, or a MELD score >/=20 ha

218 hotic liver in the presence of a serum alpha-fetoprotein level >400 ng/mL also is diagnostic.

219 An alpha-fetoprotein level >500 ng/mL predicted poorer outcomes f

220 fferentiated histology; elevated serum alpha-fetoprotein level (>100 ng/mL); a complete resection at

221 ed significant effects of pretreatment alpha-fetoprotein level (P = .03) and ADC ratio (P < .0001) on

222 nal normalized ratio greater than 1.1, alpha-fetoprotein level greater than 20 ng/mL, multiple tumors

223 A preablative serum alpha-fetoprotein level higher than 200 ng/mL (hazard ratio: 9

224 candidates for liver transplantation; alpha-fetoprotein level limitations should be incorporated in

225 nge, 13-60 U/L [0.21-1.0 mukat/L]), an alpha-fetoprotein level of 3.81 ng/ mL (normal range, 0-9 ng/m

226 ar invasion, extrahepatic disease, and alpha-fetoprotein level to best supportive care plus oral rego

227 slightly depressed at 121,000 muL, and alpha-fetoprotein level was 89 mug/L.

228 hieved in 10 patients (83.3%), and the alpha-fetoprotein level was also decreased to normal in these

229 arkers for ovarian cancer were normal (alpha-fetoprotein level, 1.6 microg/L; Ca-125 level, 15 U/mL;

230 , the two most recent models combining alpha-fetoprotein level, number of nodules, and size of the la

231 tudy site, age, sex, Child-Pugh score, alpha-fetoprotein level, tumor burden, and HCC treatment modal

232 onment also correlated with high serum alpha-fetoprotein levels (P < 0.001), macrovascular invasion (

233 scores (P = .003), higher pretreatment alpha-fetoprotein levels (P = .04), and a greater number of pr

234 It is unknown whether alpha-fetoprotein levels also predict the risk of SIDS.

235 etween second-trimester maternal serum alpha-fetoprotein levels and the risk of SIDS, which may be me

236 atients were followed with CT scan and alpha-fetoprotein levels every 3 months for 2 years posttransp

237 tein, 85% were found to have declining alpha-fetoprotein levels from a pretreatment mean of 1405 to 3

238 toms, normal eye movements, and normal alpha-fetoprotein levels in some individuals.

239 2.7 per 10,000 births among women with alpha-fetoprotein levels in the lowest quintile and 7.5 per 10

240 creased aspartate aminotransferase and alpha-fetoprotein levels were associated with HCC (p < 0.001).

241 Serum alpha fetoprotein levels were below 10 ng/mL in all 4 patients

242 ferase/alanine aminotransferase ratio, alpha-fetoprotein levels, and IL28B single-nucleotide polymorp

243 Program components, Child-Pugh class, alpha-fetoprotein levels, and percentage of tumor replacement.

244 rs of tumor aggressiveness (high serum alpha-fetoprotein levels, P = 0.038; satellite nodules, P < 0.

245 6:0)], where it correlated with plasma alpha-fetoprotein levels.

246 of cellular differentiation, and serum alpha-fetoprotein levels.

247 of a relatively stable genome and low alpha-fetoprotein levels.

248 e genome, downstream of H19 and at the alpha-fetoprotein locus on chromosome 5.

249 nserted into the normally nonimprinted alpha fetoprotein locus.

250 nfidence interval [CI], 1.03-1.30) and alpha-fetoprotein < 20 ng/mL (OR, 1.90; 95% CI, 1.12-3.21).

251 should be screened with ultrasound and alpha-fetoprotein measurement every 6 months.

252 ance for HCC is by ultrasonography and alpha-fetoprotein measurements every 6-12 months.

253 es (Model for End-Stage Liver Disease, alpha-fetoprotein, Milan-Criteria status, and radiological res

254 l response to loco-regional therapies, alpha-fetoprotein modification, inflammatory markers, and leng

255 tients, and follow-up, including serum alpha-fetoprotein monitoring for early detection of malignant

256 from primary resection to recurrence, alpha-fetoprotein more than 100 ng/mL at recurrence, recurrent

257 nodules, albumin less than 3.5 gm/dL, alpha-fetoprotein more than 100 ng/mL, and any vascular invasi

258 rs, tumor size larger than 7.0 cm, and alpha-fetoprotein more than 100 ng/mL.

259 (mRNA) levels and reduced Albumin and Alpha-fetoprotein mRNA levels, indicating that they are less d

260 s were greatly elevated maternal serum alpha-fetoprotein (MSAFP) or amniotic fluid alpha-fetoprotein

261 euronal cellular adhesion molecule and alpha-fetoprotein, neuroectodermal, and endodermal markers, re

262 Only tumor variables of alpha-fetoprotein, number, total diameter, microvascular invas

263 onseminoma (group A) and elevations of alpha-fetoprotein of 100 ng/mL or greater or of human chorioni

264 ), especially when combined with serum alpha fetoprotein or tumor staging.

265 of either one liver cancer marker, the alpha-fetoprotein, or the detection of Hepatitis C Virus infec

266 f BCLC ( P < .0001), CTP ( P < .0001), alpha-fetoprotein ( P < .0001), geographical origin ( P < .000

267 positive included CTP ( P = .0071) and alpha-fetoprotein ( P < .0001).

268 reas bridging LRT (P = .03) and serum alpha1-fetoprotein (P = .02) were independent risk factors for

269 eneous recurrence risk, dependent upon alpha-fetoprotein (P = 0.026) and tumor number (P = 0.024), re

270 the standard HCC serum protein marker alpha fetoprotein (P = 0.57).

271 c acid, suggesting that the high serum alpha-fetoprotein phenotype of G1, associated with the known o

272 Cytokeratin 19-, A6- and alpha-fetoprotein-positive cells within tumors were hepatocyte

273 ng increase in the number of c-kit and alpha-fetoprotein-positive progenitors, without altering album

274 Neonatal alpha-fetoprotein prevents circulating estrogens from accessin

275 age 40; p < 0.001), with greater serum alpha-Fetoprotein production (median level: HBV-1000 ng/ml vs.

276 ivation early in liver development and alpha-fetoprotein reactivation during liver regeneration, but

277 The best alpha-fetoprotein reduction ranged from 32% to 95%.

278 vel of Gpc3 induction is controlled by alpha-fetoprotein regulator 2 (Afr2).

279 albumin gene family that we have named Alpha-fetoprotein Related Gene (ARG) since it exhibits greates

280 own-staging is predicted by wait time, alpha-fetoprotein response to LRT, and tumor burden and result

281 te predictors of down-staging included alpha-fetoprotein response to LRT, pathologic tumor number and

282 ound no survival benefit with periodic alpha-fetoprotein screening.

283 sing the brain, therefore, to overcome alpha-fetoprotein sequestration of E2, estrogen replacement st

284 An alpha-fetoprotein serum level of 100 ng/mL identified by recei

285 Patients were subdivided according to alpha-fetoprotein serum levels (i.e., normal </= 20 ng/mL; mil

286 Alpha-fetoprotein serum levels have no prognostic meaning in w

287 sons with chronic HBV semiannually for alpha-fetoprotein since 1982.

288 rs of posttransplant survival included alpha-fetoprotein, size of the largest tumor, number of tumors

289 oss of expression of the tumour marker alpha-fetoprotein, the increase in expression of liver cell ma

290 Of 11 patients with elevated alpha-fetoprotein, three (27%) had decreases of 50% or more.

291 er quadruple screening (measurement of alpha-fetoprotein, total human chorionic gonadotropin, unconju

292 clear factor-4alpha (HNF-4) and the alpha(1)-fetoprotein transcription factor (FTF) are activators of

293 tors, steroidogenic factor-1 (or NR5A1), and fetoprotein transcription factor (or NR5A2) implicated a

294 s recently been shown to interact with alpha-fetoprotein transcription factor and repress cholesterol

295 lear factor 4alpha (HNF-4alpha) and alpha(1)-fetoprotein transcription factor, are required for both

296 cluded a favorable post-LRT radiologic/alpha fetoprotein tumor response, longer time interval from LR

297 California at San Francisco criteria, alpha-fetoprotein, up-to-7 criteria, TTV, and platelet count w

298 alpha-fetoprotein values were not exclusionary.

299 Increased serum alpha-fetoprotein was a negative prognostic variable.

300 Combined expression of SCD and alpha-fetoprotein were associated with outcomes of patients wi